Table 3.

Summary of selected published reports of adoptive γδ T cell therapy in clinical trials

Cancers	Treatment regimen	Year reported	No. of patients	Responses	Reference
T-NHL, AML, SPL and MM	Haploidentical γδ T lymphocytes, Zoledronate, and IL-2	2014	T-NHL(1 pt), AML (1 pt), SPL(1), MM(1 pt)	CR expect for MM pt which was not evaluable	(161)
Colorectal Cancer	Zoledronate- activated, ex vivo-expanded Vγ9Vδ2 T cells	2013	6 pts	CR was observed in one pt	(162)
RCC, Melanoma and AML	Bisphosphonate- reactive γδ T lymphocytes, Low-dose IL-2 and Zoledronate	2012	RCC(7 pts), Melanoma(6 pts), AML(8 pts)	No objective response for RCC and Melanoma pts, PD for 2 AML pts	(163)
	IL-2 and Zoledronate - activated Vγ9Vδ2 T celle and	2011	Melanoma (pts), Ovarian cancer (2 pts), Cervical cancer(1 pt), Colon cancer (3 pts), Breast cancer (2 pts), Duodenal cancer (1 pt), Cholangiocarcino ma (1), Adenocarcinoma (1 pt),	Melanoma: PD (4 pts), SD (2 pts), NE(1 pt); Ovarian cancer: PD (1 pt), SD (1 pt); Cervical cancer: PD; Colon cancer: PD (3 pts); Breast Cancer: PD(1 pt), CR (1 pt); Duodenal cancer: PD; Cholangiocarcino ma: PD; Adenocarcinoma: PD	(148)
ALL and AML	Allogeneic HSCT depleted of αβT cells	2007	ALL(77 pts), AML(76 pts)	CR in 36 patients	(118)

T-NHL, T cell non-Hodgkin lymphoma; AML, acute myeloid leukemia; SPL, secondary plasma cell leukemia; MM, multiple myeloma; RCC, Renal cell carcinoma; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplant; CR, complete response; PD, progressive disease; SD, stable disease; Pt(s), patient(s).